I had the privilege of participating in the 2nd Annual Medical Devices Summit earlier this month in Boston. Not knowing what to expect from the event, I was pleased to be going back to Boston, the cradle of American civilization. After making my way to Quincy Market, I set my sights on a fresh lobster roll and thumbed through the event guide. The event was focused on hot button issues, sharing information among medical device manufacturers and brought together some of the key thought leaders in the industry for two days of presentations, workshops and networking. I and Carrie Nauyalis, Planview Product Line Manager extraordinaire, were eager to meet and greet attendees and learn more about product development in the medical devices industry.<\/p>\n
The keynote Monday morning was given by Kamal Ayoub PhD, and Vice President of Operational Excellence at Covidien, a world leader in medical device manufacturing. Dr. Ayoub really set the stage for me at the summit with his opening keynote. He started off sharing success stories about the well-known innovation and poster child for innovation success. Guess who? Yes, some kind of fruit company\u2026 er, Apple. He talked about Apple and Netflix, the decline of Kodak, and posed a question to the audience. What if people could see new innovations coming that threatened their product line? How could these corporations better prepare themselves to bring the right new products to market?<\/p>\n
He drove it home by sharing that successfully developing new products is critical to the prosperity and organic growth of the modern corporation. It’s also one of the biggest challenges facing corporations in an increasingly changing environment. He also pointed out that new products fail at an alarming rate \u2013 with only ONE in four product development projects becoming a commercial success.<\/p>\n
Think about that. Now think about that as a medical devices corporation. What if your product fails and it has already been implanted or used to treat someone? The repercussions are costly and not just from a dollars perspective, but from a value of human life perspective. It’s not a matter of “if” medical devices products are going to fail, it’s often about “when” they will fail and\/or get recalled. If they fail after harming a patient or they suffer a recall after having been introduced into the market, it can cost millions and millions of dollars \u2013 not only to the corporation but to its shareholders. And of course, to the families of the affected patients!<\/p>\n